Result: In addition, other mutations including M50I (18.5%, 85/460), L74I/M (2.8%, 13/460), S119R, (0.9%,4/460), V151I, (1.3%, 6/460), and D230N (0.4%, 2/460) were also detected.
Discussion: L74M/I (2.9%) and M50I (18.8%) were the other polymorphic mutations detected in our study.
Discussion: L74M/I has been reported at levels between 0.5-20% in the untreated population, with a high prevalence in subtypes A, G, and A/G recombinants.
Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
PMID: 34694877
2022
Antimicrobial agents and chemotherapy
Table: L74I
Table: L74L/I
Table: L74M/I
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
PMID: 34694878
2022
Antimicrobial agents and chemotherapy
Abstract: The on-study secondary integrase substitution E157Q or L74I was observed in 2 participants.
Result: In 2 participants, a single INSTI-associated polymorphic substitution of E157Q or L74I (n = 1 each) was identified during the study, but given that no pretreatment samples from either participant were available for integrase assessment, it was not possible to determine if emergence had occurred during the study period.
Table: L74I
Diversity of HIV-1 Subtypes and Transmitted Drug-resistance Mutations Among Minority HIV-1 Variants in a Turkish Cohort.
Abstract: M41L, L74I, K65R, M184V, and M184I related to NRTI, K103N to NNRTI, and N83D, M46I, I84V, V82A, L24I, L90M, I54V to the PI sites were identified using NGS.
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
PMID: 34897227
2022
Journal of acquired immune deficiency syndromes (1999)
Discussion: (2021) performed a study on individuals from Uganda and identified the INSTI variant L74I to be associated with HLA A*02, B*44:15, and C*04:07 in predominately subtype A1 viruses.
Discussion: In our study, the L74I variant was associated with HLA B*15:01 (p = 0.011), an association also found in subtype B viruses in Switzerland and Australian cohorts.
Analysis of HIV-1 integrase genotypes and polymorphisms among integrase inhibitors-based antiretroviral treatment naive patients in South Sudan.
Abstract: Major INSTI resistance mutations were absent, however, polymorphic accessory mutations at positions M50ILR (26.6%) and L74I (3.3%) were detected.
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
PMID: 34978890
2022
Antimicrobial agents and chemotherapy
Discussion: A total of 54 participants who received cabotegravir LA + rilpivirine LA in the FLAIR study had the L74I polymorphism at baseline, 50 of whom had HIV-1 RNA <50 copies/mL at Week 48 and 3 of whom met CVF criteria on cabotegravir LA + rilpivirine LA.
Discussion: After re-evaluation of HIV-1 subtype, 40 participants in the FLAIR study were identified as having HIV-1 subtype A6, with the L74I polymorphism present in 36 participants (including the 3 participants with CVF) and the wild-type L74 position present in the other 4 participants (including 2 participants who were classified as having HIV-1 subtype A1 in the original analysis).
Discussion: Because only 1 out of 9 breakthrough viruses with L74I in HIV-1 subtype B selected for Q148R, it is unlikely that the low cabotegravir levels selected for Q148R
No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments.
PMID: 33693680
2021
The Journal of antimicrobial chemotherapy
Abstract: The HIV-1 integrase sequences from CSF presented resistance mutations for 9/27 (33.3%) and 8/32 (25.0%) for ARV-naive (L74I, n = 3; L74I/M, n = 1; T97A, n = 1; E157Q, n = 4) and ARV-treated (L74I, n = 6; L74M, n = 1; T97A, n = 1; N155H, n = 1) patients, respectively.
Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals.
PMID: 33800269
2021
International journal of environmental research and public health
Result: This sequence did not harbor any major or accessory drug resistance mutations to INSTIs; however, it presented a polymorphic accessory mutation (L74I) common among 20% of the studied patients but with no significant effect by itself.
HIV mutation literature information.
PMID: 
2022
Viruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT